York-based OptiBiotix Health, which develops compounds to tackle obesity, high cholesterol, diabetes and skincare, says its shares have been approved to trade on the OTCQB Venture Market in the United States.
They will begin trading on the stock market on Thursday 21 August 2025 under the symbol “OPTBF”.
Trading on the OTCQB market will not impact on the business’s existing ordinary shares admitted to trading on the AIM Market of the London Stock Exchange and no new ordinary shares were issued through this process.
OTCQB is provided through OTC Markets Group Inc located in New York. OTC Markets operates the world’s largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies.
OTCQB is a well-established market designed to provide enhanced visibility and liquidity for international companies seeking to broaden their US investor base.
Stephen O’Hara, OptiBiotix CEO, said: “OptiBiotix is building its consumer presence in the USA as shown by the recent launch of its appetite reducing SlimBiome in Hydroxycut, the number one selling weight loss supplement brand in the USA.
“This follows on from launches earlier this year with new US partners such as NHT and Daily Nouri.
“As we increase our brand presence in the USA the Board believe joining the OTCQB Market will help increase our visibility to the US investment community, broadening our shareholder base and improving liquidity.”